<DOC>
	<DOCNO>NCT02312206</DOCNO>
	<brief_summary>This multi-center , international , randomize , double-blind , placebo-controlled , two-arm efficacy safety study subject newly diagnose AL amyloidosis . Subjects remain on-study study completion , occur primary endpoint event ( all-cause mortality cardiac hospitalization ) reach .</brief_summary>
	<brief_title>The VITAL Amyloidosis Study , Global Phase 3 , Efficacy Safety Study NEOD001 Patients With AL Amyloidosis</brief_title>
	<detailed_description>This multi-center , international , randomize , double-blind , placebo-controlled , two-arm efficacy safety study subject newly diagnose AL amyloidosis . Approximately 236 subject enrol ~60 center , approximately 118 subject per arm . This event driven trial , therefore subject remain on-study study completion , occur primary endpoint event ( all-cause mortality cardiac hospitalization ) reach . All subject discontinue follow last event adjudicate . The estimate overall study duration approximately 42 month , include enrollment treatment period Study drug administer every 28 day 60-120 minute IV infusion . First-line chemotherapy must proteasome inhibitor-containing regimen , proteasome inhibitor administer weekly . The number cycle first-line chemotherapy administer discretion Investigator , subsequent chemotherapy regimen may prescribe per standard care Investigator 's discretion . An independent Data Monitoring Committee ( DMC ) review data regular basis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Key 1 . Age ≥ 18 year 2 . Newly diagnose , AL amyloidosis treatment naïve 3 . Bone marrow consistent plasma cell dyscrasia 4 . Confirmed diagnosis AL amyloidosis 5 . Cardiac involvement 6 . Planned firstline chemotherapy contain proteasomeinhibiting agent administer weekly 7 . Adequate bone marrow reserve , hepatic renal function Key 1 . NonAL amyloidosis 2 . Meets diagnostic criterion symptomatic multiple myeloma 3 . Subject eligible plan undergo ASCT 4 . History Grade ≥ 3 infusionassociated AEs hypersensitivity another monoclonal antibody , know hypersensitivity diphenhydramine acetaminophen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>